Streetbeat News

Stock Prices

BTMD

Biote shares have experienced an increase in trading volume and price following the announcement of their Q4 GAAP EPS results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 5:52 pm

TNON

Tenon Medical's stock price declined following the announcement of Q4 revenue results that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 5:45 pm

Genpact's (NYSE:G) short interest has decreased by 17.18% since the last report, with 2.15 million shares sold short, representing 1.35% of its float. This decline in short interest could indicate a more bullish sentiment towards the stock compared to its peers, where the average short interest as a percentage of float is 4.44%.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 5:45 pm

WMT

Stifel analyst Mark Astrachan has maintained a Hold rating on Walmart (NYSE:WMT) and adjusted the price target to $65 to reflect the company's 3-for-1 stock split.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 5:45 pm

UNM

Unum Group's (NYSE:UNM) short interest has decreased by 14.49% since the last report, with 2.97 million shares sold short, representing 1.77% of available shares. The current short interest suggests a more bullish market sentiment towards UNM compared to its peers, with an average short interest of 2.14%. This change in short interest could influence the stock's near-term performance.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 5:45 pm

TSE

Trinseo (NYSE:TSE) has seen a decrease in short interest, now at 3.48% of its float, lower than its peer group average of 5.62%. This reduction from 744 thousand shares suggests a more bullish sentiment among traders, as it now takes 2.14 days on average to cover short positions.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 5:45 pm

BMY

JNJ

LEGN

The FDA's Oncologic Drugs Advisory Committee is set to review supplemental biologics license applications for two cell therapies for multiple myeloma from Johnson & Johnson/Legend Biotech and Bristol-Myers Squibb. The discussions will focus on the risk-benefit assessments of Carvykti (ciltacabtagene autoleucel) and Abecma (idecabtagene vicleucel), considering clinical benefits against risks of early death and adverse events. HC Wainwright maintains a Buy rating for Legend Biotech with a price target of $87.

Portfolio Pulse from Vandana Singh

March 13, 2024 | 5:44 pm

MRO

Benchmark analyst Subash Chandra upgraded Marathon Oil Corp (NYSE:MRO) with a Buy rating and raised the price target from $25 to $32, citing a strong reserve report indicating a lower cost structure, resilient asset base, and high FCF yields at $80 oil. The report highlighted positive performance revisions, an oilier reserve mix, and efficient capital expenditure towards main assets. MRO's shares rose 3.08% to $25.91.

Portfolio Pulse from Shivani Kumaresan

March 13, 2024 | 5:41 pm

CLPT

ClearPoint Neuro's shares surged following the announcement of better-than-expected Q4 financial results and the reaffirmation of FY24 revenue guidance. Additionally, Stifel has reiterated a Buy rating on CLPT and increased the price target from $8 to $9.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 5:40 pm

ABL

CCG

CRD

DGICA

HIPO

IGIC

JRVR

KINS

MRAI

RELI

UFCS

UVE

In Wednesday's intraday session, the insurance industry saw notable movements. Marpai, Abacus Life, Cheche Group, Intl General Insurance, Kingstone Companies, and Hippo Holdings were gainers, with increases ranging from 2.94% to 8.84%. Conversely, James River Gr Hldgs, Universal Insurance Hldgs, Reliance Global Group, United Fire Gr, Donegal Gr, and Crawford were losers, with decreases ranging from 1.35% to 3.73%. Intl General Insurance's Q4 earnings were released yesterday.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 5:40 pm